Cardiac events and cardiac T2* in Egyptian children and young adults with β-thalassemia major taking deferoxamine

Hematology/ Oncology and Stem Cell Therapy

Volumn 3, Issue 4, 2010, Pages 174-178

  El Salfy, Mohsen S ^a   Abdin, Iman A ^a   El Safy, Usama R ^a   Ibrahim, Ahmed S ^a   Ebeid, Fatma S ^a   Salem, Doria S ^a  

^a ZAGAZIG UNIVERSITY   (Egypt)

Author keywords

[No Author keywords available]

Indexed keywords

DEFERASIROX; DEFERIPRONE; DEFEROXAMINE;

ADOLESCENT; ADULT; ARTICLE; BETA THALASSEMIA; CHILD; EGYPT; FEMALE; FOLLOW UP; HEART DEATH; HEART HEMOSIDEROSIS; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; IRON OVERLOAD; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MORNING DOSAGE; OBSERVATIONAL STUDY; PATIENT COMPLIANCE; PRESCHOOL CHILD; PROSPECTIVE STUDY; SCHOOL CHILD; SINGLE DRUG DOSE;

EID: 79953834895     PISSN: 16583876     EISSN: None     Source Type: Journal    
DOI: 10.5144/1658-3876.2010.174     Document Type: Article

References (24)

1. Aessopos A, Berdoukas V, Tsironi M. The heart in transfusion dependent homozygous thalassemia today-prediction and management. Eur J Haematol. 2008 Feb;80(2):93-106. Epub 2007 Dec 10.
2. Borgna-Pignatti C, Rugolotto S, De Stefano P, Zhao H, Cappellini MDMD, Del Vecchio GC, Romeo MAMA, Forni GL, Gamberini MRMR, Ghilardi R, Piga A, Cnaan A. Survival and complications in patients with thalaassemia major treated with transfusion and deferooxamine. Haematologica. 2004 Oct;89(10):1187-93.
3. El-Alfy MS, Sari TT, Chan LL, Tricta F, El-Beshlawy A. The Safety, Tolerability, and Efficacy of a Liquid Formulation of Deferiprone in Young Children with Transfusional Iron Overload. Pediatric Blood and Cancer in Press.
4. El-Beshlawy A, Manz C, Naja M, Eltagui M, Tarabishi C, Youssry I, Sobh H, Hamdy M, Sharaf I, Mostafa A, Shaker O, Hoffbrand AVAV, Taher A. Iron chelation in thalassemia: combined or monottherapy? The Egyptian experience. Ann Hematol. 2008;87(7):545-50.
5. Abdelrazik N. Pattern of iron chelation therapy in Egyptian beta thalassemic patients: Mansoura Univversity Children's Hospital experience. Hematology. 2007 Dec;12(6):577-85.
6. Tanner MAMA, Galanello R, Dessi C, Westwood MAMA, Smith GC, Nair SV, Anderson LJ, Walker JM, Pennnell DJ. Myocardial iron loading in patients with thalassemia major on deferoxamine chelation. J Cardiovasc Magn Reson. 2006;8(3):543-7.
7. Pennell DJ, Berdoukas V, Karaggiorga M, Ladis V, Piga A, Aessopos A, Gotsis EDED, Tanner MAMA, Smith GC, Westwood MAMA, Wonke B, Galanello R. Randomized controlled trial of deferiprone or deferoximine in beta-thalassaemmia major patients with asymptomatic myocardial siderosis. Blood. 2006; 107:3738-3744.
8. Davis BA, O'Sullivan C, Jarritt PH, Porter JB. Value of sequential monitoring of left ventricular ejection fraction in the management of thalassemia major. Blood. 2004;104:263-269.
9. Anderson LJ, Holden S, Davis B, Prescott E, Charrrier CC, Bunce NH, Firmin DNDN, Wonke B, Porter J, Walker JM, Pennell DJ. Cardiovascular T2-star (T2*) magnetic resonance for the early diagnosis of myocardial iron overload. Eur Heart J 2001; 22: 2171-2179.
10. Wood JC, Origa R, Agus A, Matta G, Coates TD, Galanello R.Onset of cardiac iron loading in pediatrric patients with thalassemia major. Hematologica. 2008;93(6):917-20.
11. Tanner MAMA, Galanello R, Dessi C, Westwood MAMA, Smith GC, Nair SV, Anderson LJ, Walker JM, Pennell DJ. Myocardial iron loading in patients with thalassemia major on deferoxamine chelation. J Cardiovasc Magn Reson. 2006;8(3):543-7.
12. Berdoukas V, Bohane T, Tobias V, De Silva K, Fraser I, Aessopos A, Lindeman R. Liver iron conccentration and fibrosis in a cohort of transfusion-dependent patients on long-term desferrioxamine therapy. J Hematol. 2005;5(7):572-8.
13. Daniel WW. Biostatistics: A foundation for analyysis in the health sciences. 6thedition. John Wiley and sons, Inc., New York. 1995.
14. Berdoukas V, Dakin C, Freema A, Fraser I, Aessopos A, Bohane T. Lack of correlation between iron overload cardiac dysfunction and needle liver biopsy iron concentration. Hematologica. 2005;90(5):685-6.
15. Cappellini MDMD, Porter J, El-Beshlawy A, Li CK, Seymour JF, Elalfy M, Gattermann N, Giraudier S, Lee JW, Chan LL, Lin KH, Rose C, Taher A, Thein SL, Viprakasit V, Habr D, Domokos G, Roubert B, Kattamis A; EPIC Study Investigators. Tailoring iron chelation by iron intake and serum ferritin: the prosspective EPIC study of deferasirox in 1744 patients with transfusion-dependent anemias. Haematollogica.2010;95(4):557-66.
16. Wood JC, Ghugre N, Carson S, Tyszka JM, Nelsson MDMD, Coates TD. Predictors of abnormal myocarddial function and T2* in children and young adults with thalassemia major. Blood. 2003; 102: 952.
17. Kirk P, Roughton M, Porter JB, Walker JM, Tannner MAMA, Patel J, Wu D, Taylor J, Westwood MAMA, And CC, Bunce NH, Firmin DNDN, Wonke B, Porter J, Walker JM, Pennell DJ. Cardiovascular T2-star (T2*) magnetic resonance for the early diagnosis of myocardial iron overload. Eur Heart J 2001; 22: 2171-2179.
18. Modell B, Khan M, Darlison M, Westwood MAMA, Ingram D, Pennell DJ. Improved survival of thalassaemia major in the UK and relation to T2* cardiovascular magnetic resonance. J Cardiovasc magn reson. 2008;25;10(1):42.
19. Farmaki K, Tzoumari I, Pappa C, Chouliaras G, Berdoukas V. Normalisation of total body iron load with very intensive combined chelation reverses cardiac and endocrine complications of thalaassaemia major. Br J Haematol. 2009; 12.
20. Pennell DJ, Porter JB, Capellini MDMD, El-Beshlawy A, Chan LL, Aydinok Y, Elalfy MS, Sutcharitchan P, Li CK, Ibrahim H, Viprakasit V, Kattamis A, Smith G, Habr D, Domokos G, Roubert B, Taher A. Efficacy of deferasirox in reducing and preventing cardiac iron overload in {beta}-thalasssemia. Blood. 2009; 12-28.
21. Tanner MAMA, Galanello R, Dessi C, Smith GC, Westwood MAMA, Agus A, Pibiri M, Nair SV, Walker JM, Pennell DJ. Combined chelation therapy in thalassemia major for the treatment of severe myocardial siderosis with left ventricular dysfuncttion. J Cardiovasc Magn Reson. 2008 Feb 25;10:12.
22. Aessopos A, Berdoukas V, Tsironi M. Preventtion of cardiomyopathy in transfusion-dependent homozygous thalassaemia today and the role of cardiac magnetic resonance imaging. Adv Hemattol. 2009;964897. Epub 2009 Apr 29.
23. Balocco M, Carrara P, Pinto V, Forni GL. Daily alternating deferasirox and deferiprone therapy for "hard-to-chelate" beta-thalassemia major pattients. Am J Hematol. 2010; 85(6):460
24. Taher A, Al Jefri A, Elalfy MS, Al Zir K, Daar S, Rofail D, Baladi JF, Habr D, Kriemler-Krahn U, El-Beshlawy A. Improved Treatment Satisfaction and Convenience with Deferasirox in Iron-Overlloaded Patients with beta-Thalassemia: Results from the ESCALATOR Trial. Acta Haematol 2010; 27;123(4):220-225